Skip to content

Medtronic Reveal XT Study

A Comparison of Traditional Arrhythmia Assessment With the Use of Continuous Monitoring to Quantify Postoperative Arrhythmia Burden Following Surgical Treatment of Atrial Fibrillation- Medtronic Reveal XT Study

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01526343
Enrollment
47
Registered
2012-02-03
Start date
2011-06-30
Completion date
2016-01-31
Last updated
2017-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

Patients

Brief summary

While surgical treatment for atrial fibrillation (AF) has been performed for over 20 years, virtually all of the historical series reported only the recurrence of symptomatic AF and have used only intermittent electrocardiogram (ECG) follow-up. This study compares the use of traditional arrhythmia assessment (ECG and 24-hour holter monitoring) with the use of the Medtronic Reveal XT device to continuously record heart rhythm to quantify postoperative arrhythmia burden following surgical treatment for AF in patients undergoing either lone or concomitant heart surgery.

Interventions

DEVICEReveal XT implantation

The implantation of the Reveal XT device will be performed at the time of surgery before the planned median sternotomy or thoracotomy.

Sponsors

Northwestern University
CollaboratorOTHER
Washington University School of Medicine
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients undergoing planned, elective AF surgery, either as a stand-alone procedure or as a concomitant cardiac operation. 2. Patients will have either a Cox-Maze procedure (full-biatrial lesion set) or surgical pulmonary vein isolation (PVI). 3. Patients 18 years or older. 4. All eligible patients will be considered, regardless of gender or race. 5. Patients able and willing to provide informed consent and willing to comply with the required interval follow-up.

Exclusion criteria

1. Patients with a preoperative permanent pacemaker. 2. Patients with a projected lifespan of less than six months. 3. Patients requiring emergent cardiac surgery. 4. Patients unwilling or unable to give written informed consent. 5. Patients undergoing a right atrial or left atrial lesion set procedure.

Design outcomes

Primary

MeasureTime frame
Number of ATA (Atrial Tachyarrhythmias) Episodes and Burden, Determined at Defined Postoperative IntervalsILR monitoring obtained at 3, 6 and 12 months
Freedom From Atrial Tachyarrhythmias (ATAs)ILR monitoring at 12 months

Countries

United States

Participant flow

Recruitment details

A total of 47 consecutive patients who received an implantable loop recorder (ILR) after a surgical ablation procedure were followed between August 2011 and January 2014. Patients with AF who were scheduled to undergo elective surgical ablation procedure that included a CM IV lesion set or pulmonary vein isolation were eligible.

Participants by arm

ArmCount
Reveal XT
Reveal XT implantation: The implantation of the Reveal XT device will be performed at the time of surgery before the planned median sternotomy or thoracotomy.
47
Total47

Baseline characteristics

CharacteristicReveal XT
Age, Continuous67 years
STANDARD_DEVIATION 10
Region of Enrollment
United States
47 participants
Sex: Female, Male
Female
20 Participants
Sex: Female, Male
Male
27 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 47
other
Total, other adverse events
0 / 47
serious
Total, serious adverse events
0 / 47

Outcome results

Primary

Freedom From Atrial Tachyarrhythmias (ATAs)

Time frame: ILR monitoring at 12 months

Population: Participants with available data at 1 year and who were compliant with use of each device.

ArmMeasureGroupValue (NUMBER)
Reveal XTFreedom From Atrial Tachyarrhythmias (ATAs)Freedom from ATAs at 1 year, ILR device37 Participants
Reveal XTFreedom From Atrial Tachyarrhythmias (ATAs)Freedom from ATAs at 1 year, Holter monitor33 Participants
Reveal XTFreedom From Atrial Tachyarrhythmias (ATAs)Freedom from ATAs at 1 year, ECG37 Participants
Primary

Number of ATA (Atrial Tachyarrhythmias) Episodes and Burden, Determined at Defined Postoperative Intervals

Time frame: ILR monitoring obtained at 3, 6 and 12 months

ArmMeasureGroupValue (NUMBER)
Reveal XTNumber of ATA (Atrial Tachyarrhythmias) Episodes and Burden, Determined at Defined Postoperative IntervalsCount of total ATAs20,878 ATA episodes
Reveal XTNumber of ATA (Atrial Tachyarrhythmias) Episodes and Burden, Determined at Defined Postoperative IntervalsCount of reviewed and confirmed ATAs1,034 ATA episodes

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026